AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$ONC

Wang Xiaodong sold $13.4M of ONC

Wang Xiaodong sold 38,287 shares of BeOne Medicines Ltd. (ONC) at an average of $349.10 ($345.38–$351.25, $13.37M total) across 8 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wang Xiaodong
Published Sep 10, 2026, 8:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ONC
Bearish
medium confidence
Mentioned
$ONC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCBearishLow
01

Why it matters

The director's complete exit may be interpreted as a lack of confidence, but could also be a routine portfolio rebalancing.

02

Market read

Insider sale of $13.4M by a director is a material event for ONC investors, potentially influencing short‑term price action.

03

What to watch

Potential upcoming clinical data releases or partnership announcements that could offset the negative signal from the insider sale.

Relevance 6/10Novelty 5/10Timing: post‑market Sep 10 filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of corporate activity.

Company-level read

Ticker impact

$ONCBearishMedium confidence
Context

Director Wang Xiaodong sold all 38,287 shares for $13.4M via a 10b5‑1 plan, leaving zero holdings.

Expected impact

Potential modest decline of 2‑4% over the next few days.

Evidence & confidence

Large director-level disposition via a pre‑arranged plan suggests a neutral to negative outlook, but no immediate market reaction is evident yet.

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are common and rarely shift sector sentiment.

Regional

Limited to U.S. markets where ONC trades; no regional ripple effect.

Global

Low global relevance; the filing is company‑specific.

Counterpoint

What could challenge this read

The sale could be purely liquidity‑driven and not reflect company fundamentals, presenting a buying opportunity if the stock is oversold.

Key entities

  • Company
    BeOne Medicines Ltd.

    Biotech firm listed on NASDAQ under ticker ONC.

  • Individual
    Wang Xiaodong

    Director of BeOne Medicines who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min